- hypersensitivity to chloroquine or hydroxychloroquine - history of retinal disease (macular degeneration, diabetic retinopathy, retinal rear/detachment, retinitis pigmentosa) - history of seizure disorder - history of ventricular tachycardia/fibrillation, history of long-qt syndrome, or icd - current creatinine clearance <10 ml/min or on hemodialysis (as evidenced in emr) - known g6pd deficiency - current use of the following medications: digoxin, amiodarone, flecainide, procainamide, oral dapsone. if other meds of concern, route to pharmacist to evaluate - concomitant use of the following only at pharmacist/investigator discretion: abiraterone acetate, agalsidase, conivaptan, dabrafenib, dacomitinib, dapsone (systemic), digoxin, enzalutamide, fexinidazole, flecainide, fusidic acid (systemic), idelalisib, mifepristone, mitotane, pimozide, amiodarone, digoxin, procainamide, propafenone, stiripentol - currently on hospice - women of childbearing potential must not be pregnant, and must avoid becoming pregnant while on treatment and for 30 days following treatment discontinuation. men must avoid fathering a child while on treatment and for 30 days following treatment discontinuation - any clinical factors such as bleeding, active infection, or psychiatric factors that in the judgment of the investigator would preclude safe participation and compliance with study procedures.

- hypersensitivity to chloroquine or hydroxychloroquine - history of retinal disease (macular degeneration, diabetic retinopathy, retinal rear/detachment, retinitis pigmentosa) - history of seizure disorder - history of ventricular tachycardia/fibrillation, history of long-qt syndrome, or icd - current creatinine clearance <10 ml/min or on hemodialysis (as evidenced in emr) - known g6pd deficiency - current use of the following medications: digoxin, amiodarone, flecainide, procainamide, oral dapsone. if other meds of concern, route to pharmacist to evaluate - concomitant use of the following only at pharmacist/investigator discretion: abiraterone acetate, agalsidase, conivaptan, dabrafenib, dacomitinib, dapsone (systemic), digoxin, enzalutamide, fexinidazole, flecainide, fusidic acid (systemic), idelalisib, mifepristone, mitotane, pimozide, amiodarone, digoxin, procainamide, propafenone, stiripentol - currently on hospice - women of childbearing potential must not be pregnant, and must avoid becoming pregnant while on treatment and for 30 days following treatment discontinuation. men must avoid fathering a child while on treatment and for 30 days following treatment discontinuation - any clinical factors such as bleeding, active infection, or psychiatric factors that in the judgment of the investigator would preclude safe participation and compliance with study procedures.